EUVIMEDEUVIMED entdecken
Open Access

Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury

Si-Yuan Jiang, Tian Tian, Wen-Jie Li, Ting Liu, Cong Wang, Gang Hu, Ren-Hong Du iD, Yang Liu iD, Ming Lu iD

The EMBO Reports · 09.10.2023 · 24 (10)

DOI: 10.15252/embr.202357101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The EMBO Reports, online erschienen am 25.08.2023. Verfasst von Si-Yuan Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Mefloquine, Lipopolysaccharides, Inflammation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinMefloquineLipopolysaccharidesInflammationInflammasomesAnimalsMiceHumansMice, Inbred C57BLParkinson DiseaseProtein Binding

Stichwörter der Autor:innen

NLRP3Parkinson's diseaseinflammationinhibitormefloquine

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinMefloquineLipopolysaccharidesInflammasomesNlrp3 protein, mouse

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China.
  • Department of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Ren-Hong Du, Yang Liu, Ming Lu

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • National Key R&D Program of China

Zitieren

APA

Jiang, S. Y., Tian, T., Li, W. J., Liu, T., Wang, C., Hu, G., Du, R. H., Liu, Y., & Lu, M. (2023). Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury. The EMBO Reports, 24(10). https://doi.org/10.15252/embr.202357101

Vancouver

Jiang SY, Tian T, Li WJ, Liu T, Wang C, Hu G, et al. Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury. The EMBO Reports. 2023;24(10). doi:10.15252/embr.202357101

BibTeX
@article{Jiang2023,
  author = {Jiang, Si-Yuan and Tian, Tian and Li, Wen-Jie and Liu, Ting and Wang, Cong and Hu, Gang and Du, Ren-Hong and Liu, Yang and Lu, Ming},
  title = {Mefloquine targets NLRP3 to reduce lipopolysaccharide‐induced systemic inflammation and neural injury},
  journal = {The EMBO Reports},
  year = {2023},
  volume = {24},
  number = {10},
  doi = {10.15252/embr.202357101}
}
Kostenlos starten →